Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
A multicenter, randomized, open-lable, single-dose, two-cycle, double-cross bioequivalence study comparing the pharmacokinetic profile of LY01612 (Doxorubicin hydrochloride liposome injection) and CAELYX® in Chinese subjects with advanced breast cancer
Advanced Breast Cancer
DRUG: Doxorubicin hydrochloride liposome injection
plasma maximum concentration (Cmax) of encapsulated doxorubicin., from baseline to day 56|Area under Plasma d concentration-time curves of encapsulated doxorubicin, from baseline to day 56|plasma maximum concentration (Cmax) of unencapsulated doxorubicin., from baseline to day 56|Area under Plasma concentration-time curves of unencapsulated doxorubicin., from baseline to day 56
plasma maximum concentration（Cmax） of total doxorubicin；, from baseline to day 56|Area under plasma concentration-time curves of total doxorubicin；, from baseline to day 56|Partial area under plasma concentration-time curves （AUC0-48h and AUC48h-t）of encapsulated doxorubicin, from baseline to day 56|Encapsulated doxorubicin、unencapsulated doxorubicin and total doxorubicin Tmax, from baseline to day 56|Encapsulated doxorubicin、unencapsulated doxorubicin and total doxorubicin t1/2z, from baseline to day 56|Adverse event, from baseline to day 56
A multicenter, randomized, open-lable, single-dose, two-cycle, double-cross bioequivalence study comparing the pharmacokinetic profile of LY01612 (Doxorubicin hydrochloride liposome injection) and CAELYX® in Chinese subjects with advanced breast cancer